Sarilumab: First Global Approval. - Wikidata - wikimedia - TriplyDB

Sarilumab: First Global Approval.

Sarilumab: First Global Approval.

http://www.wikidata.org/entity/Q39177162

about

Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

P2860

Q55052878-ACD2095A-07AD-4E16-98EF-ED79EDDFF639

P2860

Sarilumab: First Global Approval.

http://www.wikidata.org/entity/Q39177162

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Sarilumab: First Global Approval.

@en

Sarilumab: First Global Approval.

@nl

type

label

Sarilumab: First Global Approval.

@en

Sarilumab: First Global Approval.

@nl

prefLabel

Sarilumab: First Global Approval.

@en

Sarilumab: First Global Approval.

@nl

P1433

Q39177162-0028EEA2-044A-43EF-A8A9-3D307761EC65

P1476

Q39177162-2266DA32-8DB5-45C0-ABF2-F47A0C81A2C6

P2860

Q39177162-15808975-8EA1-4171-A73C-519F48F05725

Q39177162-6B616B54-70B7-460F-A01E-328F819EA276

Q39177162-6F4E0E90-C70A-4E62-9C37-2F4804C73DC7

Q39177162-7BF9480A-E663-4D9A-BC62-239D40341B30

Q39177162-B611FC0A-F9A6-41DE-90DE-8FAA64BA1162

Q39177162-D0AF1805-5FDC-4093-85DA-7C296E010180

Q39177162-F6E662B9-A7E2-44A9-9A75-5BEE4E714820

P2888

Q39177162-F1B57CCB-F8E1-4932-B399-74CD2B7BC5FB

P304

Q39177162-A066BCB1-875A-4616-BEB9-A374E50FEB3C

P31

Q39177162-76550C0A-B535-4770-9625-25B6F94BEFE6

P356

Q39177162-E61CE05B-18E6-4D26-A6C9-2D38207000B7

P433

Q39177162-9CE1A6DE-2353-48EB-B8F8-F8A786F6A9CA

P478

Q39177162-08C8B359-169C-458D-9BBE-4644416DD4F1

P50

Q39177162-ECE217FD-E318-43CC-A38A-4FC2AD534514

P577

Q39177162-14B6857D-33D6-425E-80B0-E388D726D4FA

P698

Q39177162-E612C751-0A0C-4829-979E-932FDA232339

P356

S40265-017-0724-2

P1433

P1476

Sarilumab: First Global Approval.

@en

P2860

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

The role of interleukin 6 in the pathophysiology of rheumatoid arthritis

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

P2888

s40265-017-0724-2

P304

705-712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0724-2

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28290137

http://www.w3.org/2001/XMLSchema#string